Published in Oncol Lett on August 07, 2017
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32
New driver mutations in non-small-cell lung cancer. Lancet Oncol (2011) 6.03
Smoking and lung cancer: recent evidence and a discussion of some questions. 1959. Int J Epidemiol (2009) 4.17
Axis of evil: molecular mechanisms of cancer metastasis. Oncogene (2003) 2.81
Wnt signaling in cancer. Cold Spring Harb Perspect Biol (2012) 2.75
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell (2006) 2.13
Lung cancer in never smokers--a review. Eur J Cancer (2012) 1.75
Golgi-localized GAP for Cdc42 functions downstream of ARF1 to control Arp2/3 complex and F-actin dynamics. Nat Cell Biol (2005) 1.67
Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun (2010) 1.67
Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display. Oncogene (2006) 1.56
WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Ther (2009) 1.34
A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.31
Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer (2010) 1.25
Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp (1998) 1.18
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
ARHGAP10 is necessary for alpha-catenin recruitment at adherens junctions and for Listeria invasion. Nat Cell Biol (2005) 1.06
β-Arrestin 1 inhibits the GTPase-activating protein function of ARHGAP21, promoting activation of RhoA following angiotensin II type 1A receptor stimulation. Mol Cell Biol (2010) 1.01
ARHGAP21 modulates FAK activity and impairs glioblastoma cell migration. Biochim Biophys Acta (2009) 0.92
ARHGAP10, a novel human gene coding for a potentially cytoskeletal Rho-GTPase activating protein. Biochem Biophys Res Commun (2002) 0.90
Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance. BMC Genomics (2014) 0.86
ARHGAP21 associates with FAK and PKCzeta and is redistributed after cardiac pressure overload. Biochem Biophys Res Commun (2008) 0.83
ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells. Biochim Biophys Acta (2012) 0.83
ARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells. Cell Death Dis (2016) 0.80